Welcome to our dedicated page for ANEW MEDICAL news (Ticker: WENA), a resource for investors and traders seeking the latest updates and insights on ANEW MEDICAL stock.
The WENA news archive on Stock Titan captures the transition of ANEW MEDICAL, INC. into Klotho Neurosciences, Inc. and its evolution as a Nasdaq‑listed biopharmaceutical and biotechnology company. Company press releases describe a strategic rebranding, a ticker change from WENA to KLTO, and an intensified focus on patented therapies targeting the brain and central nervous system (CNS) for neurodegenerative and age‑related disorders.
News items highlight the firm’s emphasis on the human Klotho gene, particularly the secreted isoform s‑KL, which its disclosures associate with aging, cognition and neurological function. Coverage includes updates on patents granted in the U.S., Europe, China, Hong Kong and other Asian markets for Klotho‑based gene therapy, as well as announcements about advancing gene therapy programs for ALS, Alzheimer’s disease, Parkinson’s disease and related conditions.
Investors and followers can also find releases on collaborations and technology acquisitions, such as the partnership with the Okinawa Research Center for Longevity Science (ORCLS) to study Klotho levels in long‑lived populations, and the exclusive worldwide license for the Nanoject needle‑free dry powder autoinjector for medicines and vaccines. Additional news covers peptide‑based programs for weight and eating disorders, antibody biologics targeting cancer and autoimmune diseases, and financial developments like the conversion of convertible promissory notes to remove long‑term debt.
By reviewing this news feed, readers can track how the former WENA‑listed company has built its Klotho‑centered pipeline, expanded its intellectual property, formed research partnerships and reported regulatory milestones, including an FDA Orphan Drug Designation for its KLTO‑202 gene therapy candidate for ALS.
ANEW MEDICAL (NASDAQ: WENA) has secured a key patent in Europe (EP3377091B1) for its secreted Klotho gene (s-KL) and gene delivery systems, targeting neurodegenerative diseases like dementia and Alzheimer's. This patent complements earlier approvals in China and Hong Kong. The intellectual property was exclusively licensed from institutions in Barcelona, Spain. ANEW plans to leverage this patent for product development and expand into Asian markets starting in 2024. CEO Dr. Joseph Sinkule emphasized the potential of s-KL for cell and gene therapy in treating neurological disorders, noting its critical role in brain function and neurological health.